Genetically engineered mouse models of prostate cancer.

Date publication

avril 2013

Journal

Molecular oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr METZGER Daniel

Tous les auteurs :
Parisotto M, Metzger D

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/23481269

Résumé

Despite major improvement in treatment of early stage localised prostate cancer, the distinction between indolent tumors and those that will become aggressive, as well as the lack of efficient therapies of advanced prostate cancer, remain major health problems. Genetically engineered mice (GEM) have been extensively used to investigate the molecular and cellular mechanisms underlying prostate tumor initiation and progression, and to evaluate new therapies. Moreover, the recent development of conditional somatic mutagenesis in the mouse prostate offers the possibility to generate new models that more faithfully reproduce the human disease, and thus should contribute to improve diagnosis and treatments. The strengths and weaknesses of various models will be discussed, as well as future opportunities.

Mots clés

Androgens, metabolism, Animals, Disease Models, Animal, Genetic Engineering, Humans, Male, Mice, Mutation, genetics, Prostatic Neoplasms, metabolism, Stem Cells, metabolism

Référence

Mol Oncol. 2013 Apr;7(2):190-205